MSD Animal Health to Host Global Continuing Education Symposium Focused on Companion Animal Vaccination
Virtual event featuring 12 global experts offered free to veterinary professionals
MADISON, N.J., March 16, 2023 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the company will host a virtual continuing education symposium featuring 12 experts from around the world. This event, sponsored by NOBIVAC® will be held virtually on May 31, 2023, from 7 a.m. to 1 p.m. EDT and features 11 presentations across two parallel tracks (medical and business) covering topics such as the future of vaccine innovation and improving the vaccine appointment experience. The event is free of charge.
“Vaccination is essential to protecting pets against infectious diseases. As we continue to make strides in medical advancements and vaccine innovation, it is important to ensure that our veterinary colleagues have the latest information to educate their clients and make the best clinical decisions for their patients” said Ingrid Deuzeman, global marketing director, Companion Animal Vaccines, MSD Animal Health. “That’s why we are thrilled to bring together experts from all over the world and offer this unique educational opportunity for the entire veterinary community.”
A comprehensive educational agenda dedicated to companion animal vaccination
- A Practical Guide to Using Vaccination Guidelines: How you and your practice can best benefit from these evolving information resources
- Let’s Talk Lepto: Updates on prevalence, diagnosis, and prevention
- What Every Vet Needs to Know about FeLV: A refresher and latest insights on this perpetually perplexing disease
- What’s New in Parvo?: An update on prevalence, treatment, and best protection practices
- The Future of Pet Vaccines: An insider view to new science and innovation for old diseases
- The Vaccine Experience – Reimagined: Tips to improve vaccine appointments to keep pets & clients coming back yearly
- Communicating Cash: Stop defending your prices, start communicating your value
- Vaccination Hesitancy – Your Clients’ Perspective: Understanding how clients think, the psychology behind their decision-making, and how to engage
- Vaccination Awareness Using a Team Approach: Empowering team members to communicate best vaccine practices with pet owners
- Client Engagement and Vaccination in the Digital Age: How to communicate with and educate clients beyond your clinic walls
The event will conclude with a Keynote address on the One Health approach to rabies elimination with Dr. Sarah Cleaveland, Professor of Comparative Epidemiology at the School of Biodiversity, One Health, and Veterinary Medicine, University of Glasgow, and founder of the AFYA Serengeti project, whose research is now being carried forward by Rabies Free Africa. Ingrid Deuzeman, global marketing director, MSD Animal Health will also speak.
Each person who attends the event will earn a certificate per talk attended. For those unable to attend, symposium content will be made available on-demand through September 30, 2023. The event and on-demand content will be presented in English and captioned in seven additional languages including Spanish, Portuguese, Italian, German, French, Chinese and Japanese.
Registration is open now to all interested in attending: www.VaccinationUnitesUs.com
As one of the only biopharmaceutical companies focused on both human and animal health, and in recognition of the connection between the health of people and animals and our shared environment, we apply a One Health approach to our mission to save and improve lives.
Our company is actively collaborating with human, animal, and environmental health stakeholders to tackle major population health challenges, including antimicrobial resistance, zoonotic diseases, vector-borne diseases, ensuring a safe and sustainable food supply as well as sustainable practices which protect our environment.
About MSD Animal Health
At MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines, and innovative health solutions for the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of MSD. Through its commitment to The Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability, and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com and connect with us on LinkedIn and Twitter.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).